Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037

PURPOSE: Tumours frequently have defects in multiple oncogenic pathways, e.g. MAPK and PI3K signalling pathways, and combinations of targeted therapies may be required for optimal activity. This study evaluated the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037, as single agents and...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Chemother Pharmacol
Hoofdauteurs: Haagensen, Emma J., Thomas, Huw D., Schmalix, Wolfgang A., Payne, Andrew C., Kevorkian, Lara, Allen, Rodger A., Bevan, Paul, Maxwell, Ross J., Newell, David R.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer Berlin Heidelberg 2016
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5114336/
https://ncbi.nlm.nih.gov/pubmed/27837257
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3186-4
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items